Tests On Professional Antiseptics Could Influence Consumer Hand Wash Market

Responding to industry's requests, US FDA's rulemaking on six health care personnel antiseptics remaining in the OTC drug monograph is delayed one year to allow firms to demonstrate the ingredients are GRASE. ACI says the research could impact whether ingredients remain available for consumer hand washes.

The additional year FDA is allowing for research on the safety of six antiseptic ingredients in health care personnel hand washes could generate data that determine whether three of the ingredients also will remain available in consumer hand rubs.

FDA's Center for Drug Evaluation and Research granted the extension in response to manufacturers' requests for more time to complete...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Safety

More from Pink Sheet

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

Report Shows Extent Of AI Use In EU Medicines Regulation During 2024

 

The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.

Prasad Cites Unproven Theory Defending His COVID-19 Vaccine Decisions

 

In defending his decision to overrule agency staff on three recent COVID-19 vaccine applications, the CBER director questioned the original timing of Pfizer’s COVID-19 vaccine authorization, reviving a long-held, but unproven grievance of President Trump.